Skip to main
AVXL

AVXL Stock Forecast & Price Target

AVXL Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anavex Life Sciences is well-positioned for growth with a strategic reset in the EU following negative feedback from the EMA, while pursuing ongoing regulatory engagement in the US. They have also submitted additional data to the FDA and are actively working to address CHMP feedback to strengthen their data package. Their multi-indication potential for drugs like ANAVEX 2-73 in markets like Alzheimer's, Rett Syndrome, and Parkinson's Disease Dementia gives them a wide range of possibilities for growth, and their lower probability of success in therapeutic models in the US (50%) and EU (15%) further supports their potential.

Bears say

Anavex Life Sciences is facing a negative outlook due to several factors. The company's pipeline of drugs under development for various CNS diseases has a high risk of failure and limited potential for success. Additionally, the company's financials are not strong, with a high discount rate and low probability of success in its therapeutic models, making it a risky investment. Furthermore, while the company's latest update on correlation analyses and subgroup framing is supportive, it is not a new registrational outcome or regulatory event, highlighting the company's lack of significant progress.

AVXL has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anavex Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anavex Life Sciences (AVXL) Forecast

Analysts have given AVXL a Strong Buy based on their latest research and market trends.

According to 2 analysts, AVXL has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anavex Life Sciences (AVXL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.